hey! i'm new to investing and just wanted advice on what the best stocks to invest in are, i have a roth IRA through merrill. right now im invested in VOO SPGI, amazon, SOXX and a couple others. sold some of my google shares which was stupid. but just wanted to know what i should put my money in. i’m relatively young so i know i have time. but i really want to learn as much as possible. if you have any good advice on general stocks or on these 2 specific ones im referring to please share!!

Here's my analysis on IONQ

IonQ, Inc. (NYSE: IONQ) is a prominent player in the quantum computing industry, specializing in trapped-ion technology. This approach offers advantages in coherence time and error rates, positioning IonQ at the forefront of quantum computing advancements.

Key Factors Supporting IonQ's Investment Potential:

1. Technological Leadership: IonQ has demonstrated significant progress in quantum computing capabilities. In the second quarter of 2024, the company achieved a two-qubit native gate fidelity of 99.9% using next-generation barium qubits, enhancing the accuracy of its quantum systems.

2. Strategic Partnerships and Contracts: The company has secured substantial contracts, including a $54.5 million agreement with the U.S. Air Force Research Lab in September 2024 to advance quantum networking and system scalability.

3. Financial Performance: IonQ has shown robust financial growth. In Q2 2024, the company reported $11.4 million in revenue, exceeding the high end of its guidance range and representing a 106% increase compared to the same period in the previous year.

4. Strong Cash Position: As of June 30, 2024, IonQ maintained $402 million in cash, cash equivalents, and investments, providing a solid foundation for ongoing research, development, and expansion initiatives.

Revenue from the Last Earnings Call:

During the second quarter of 2024, IonQ reported revenue of $11.4 million, surpassing its projected range of $7.6 million to $9.2 million. This performance underscores the company's accelerating growth trajectory and its ability to exceed financial expectations.

IonQ's combination of technological innovation, strategic partnerships, strong financial performance, and a solid cash position contributes to its potential as a compelling investment opportunity in the emerging quantum computing sector.

Hello /r/stocks.

My mother has 400 shares of GE stock on a physical stock certificate dated mar 5th, 2003. I recently took them to Schwab to get them digitally converted into her brokerage. How do they mathematically do all the calculations for what she has in today's value? I know GE has had a history of splits, reverse splits, and even splitting into 3 different companies with all differing valuations.

Does anyone have any estimate at how much my mother is looking at here once these shares show up into her brokerage?

https://www.anavex.com/_files/ugd/79bcf7_a8157ab4ed0c47bdb82cbe87047dfee1.pdf

The data above was presented yesterday at CTAD 2024 in Madrid - an Alzheimer's conference where Dr. Sabbagh presented ground-breaking results from Anavex Life Sciences Alzheimer's medication Blarcamesine.

Blarcamesine once daily orally significantly slowed clinical decline in ITT population:

✓ ADAS-Cog13 at 48 Weeks: by 36.3%

✓ Key Secondary Endpoint CDR-SB at 48 Weeks: by 27.6%

Confirmation of beneficial clinical effect through upstream SIGMAR1 activation:

• Blarcamesine once daily orally significantly slowed clinical decline with greater clinical benefit in

pre-specified Common SIGMAR1 wild-type (WT) carrier population:*

✓ ADAS-Cog13 at 48 Weeks: by 49.8%

✓ Key Secondary Endpoint CDR-SB at 48 Weeks: by 33.7%

*Majority of the general population (~70%) carries Common SIGMAR1 WT* gene

• Common SIGMAR1 WT gene carriers (~70% of general population) are expected to experience greater benefit from SIGMAR1 activation with blarcamesine

• Blarcamesine significantly slowed brain atrophy in key regions of interest, including the whole

brain, total grey matter, and lateral ventricles

• Clinical outcomes were also corroborated by biomarkers from the A/T/N spectrum, including a

significant increase in plasma Aβ 42/40 ratio (mean increase 0.013)

• Blarcamesine was relatively safe and no associated neuroimaging adverse events

Anavex Life Sciences is about to submit for regulatory approval in Europe and publish seminal papers in prominent scientific journals for their revolutionary discoveries involving the SIGMA1 receptor for promoting autophagy in neurodegenerative disease. (See below)

https://www.anavex.com/sigmaceptor-explained

The same drug (Blarcamesine) also works in Parkinson's, Parkinson's Disease Dementia, Rett Syndrome, Fragile X, Infantile Spasms, Angelman Syndrome. They also have another drug candidate (Anavex 3-71) soon to start Phase 3 for Schizophrenia, which is also most likely better than anything on the market. (see pipeline below)

https://www.anavex.com/therapeutic-candidates

This will be the first oral medication to treat the underlying cause of dementia and Alzheimer's disease, which has a combined approximately 50-100 million patients globally and growing. That is a HUGE TAM!!!!

Current Alzheimer's therapies do not work well, only provide brief symptomatic improvements, cause severe side effects, or are prohibitively expensive under Medicare, cumbersome to administer - such as brain and spinal injections and IV infusion therapies that take 4 hours+ to complete at an infusion center, require constant MRI/PET imaging scans to detect ARIA-H (brain swelling and brain bleeding), and may cause death.

And none of them even work as well as Blarcamesine.

Anavex Life Sciences just completely stunned the world yesterday. They completely reduced Big Pharma Alzheimer's pipelines to complete obsolescence.

Just like Nvidia changed the paradigm in traditional computing by revolutionizing multi-purpose GPU computing, Anavex Life Sciences just changed the game in neuroscience with the data they released yesterday.

Do your own research, but what happened yesterday completely revolutionized the potential treatment of Alzheimer's Disease and other CNS diseases, which has significant unmet medical needs globally. Neuroscience is finally starting to make major advancements.

For reference, Anavex Life Sciences is currently worth $570M.

Bristol Myers Squibb just paid $12 billion for a worse schizophrenia drug recently.

AbbVIe just paid $8.4 billion for a Parkinson's Disease symptomatic only drug and a Schizophrenia drug

AbbVie just paid $1.4 billion for an Alzheimer's drug that is an outdated monoclonal antibody injection that causes brain bleeding that isn't even in Phase 1 trials yet.

Im looking in to these cheaper rated stocks like Sofi and yum china ect. rather than google or meta

I got like 6000 $ to further invest. Currently i got Mstr and Nvidia and MU. Im looking for suggestions to these stocks that cost below 100 $

Hit me with some stocks you feel i should buy.

I've been evaluating as most here the horrible jobs report and seeing the mag 7 flutter.. it made me investigate some tickers which have fell from grace.

Two that really caught my eye were Dollar Tree(DLTR) & Dollar General (DG)..

Both are essential 52 week lows and fell 50% from highs and couple of months ago. You may ask, why? Well a couple of factors. Earnings weren't so hot. Mainly from eeconomic headwinds.. margin compression, and competition from the likes of walmart.

Individually each has a weakness in their own right. DG typically looking ratchet and prices higher than others. DLTR with their recent purchase of family dollar not working as well as they'd like.

Now, why are these potentially a awesome place to park your money?

First off, much cheaper than just a few months ago. 2nd and most likely the catalyst.. a economic recession.

We are getting closer to one as each day passes. We all saw the jobs report this morn. I feel like the lack of sales stems from the poor getting to poor to shop there but as a recession looms we will see the pivot from those who went to target supermarket to a dollar store.

I could be wrong which is why I wanted to get everyone's perspective. Are these two worthwhile to start a position in?

On first glance, it doesn’t look particularly attractive tbh.

A lot of unattractive companies and the ETF itself didn’t perform that good either in the young past.

So why is a split between a World ETF and EM ETF so popular? Is it really and investment or is it speculation?

Why just not pick a few good companies out and do it that way? Like TSMC, Samsung or whatever?

https://www.cnbc.com/2024/10/31/megacap-tech-gets-new-blackrock-etf.html

BlackRock’s iShares is trying to appeal to investors who want to diversify beyond from the so-called Magnificent Seven. The firm launched the iShares Top 20 U.S. Stocks ETF (TOPT) this month. It doesn’t just hold the Magnificent Seven — Apple, Amazon, Meta, Alphabet, Microsoft, Nvidia and Tesla. It’s made up of the 20 largest U.S. stocks by market capitalization. “What the iShares build ETFs are designed to do is to deliver a tool kit of simple solutions for investors to be able to capture the growth of some of the largest companies within the U.S. equity market today, but to do so in a broader and more diversified manner,” BlackRock’s Rachel Aguirre told CNBC’s “ETF Edge” on Monday.

Aguirre, the firm’s head of U.S. iShares product, noted the ETF’s mission is to deliver an easy and accessible way to tap into the innovation of megacaps – “whether that be in the tech-heavy Nasdaq space or, more broadly, within the S&P [500].” The ETF, according to Aguirre, provides a way for investors worried about the concentration of the Magnificent Seven stocks in the S&P 500.

On Thursday, the Magnificent Seven slid more than 3.5% as a group — losing around $615 billion in market cap. That’s equivalent to the size of JPMorgan Chase. However, the Magnificent Seven is still up about 43% so far year while the S&P 500 is up around 20% “It’s important for clients and investors to remember that there are split views on this topic. There are many investors who believe that the big will get bigger [and] that the winners will continue to win,” Aguirre said. “There’s also another side to this argument. There are many investors who believe that it’s actually a very worrisome time to continue investing in… mega-cap companies because of just their high valuations.”

U.S. economy added 12,000 jobs in October, far less than expected; unemployment rate at 4.1%

https://www.cnbc.com/2024/11/01/us-jobs-report-october-2024.html

​

Job creation in October slowed to its weakest pace since late 2020 as the impacts of storms in the Southeast and a significant labor impasse dented the employment picture.

Nonfarm payrolls increased by 12,000 for the month, down sharply from September and below the Dow Jones estimate for 100,000, the Bureau of Labor Statistics reported Friday. In what had already been expected to be a downbeat report, October posted the smallest gain since December 2020.

The unemployment rate, however, held at 4.1%, in line with expectations. A broader measure of unemployment that includes discouraged workers and those holding part-time jobs for economic reasons also was unchanged at 7.7%.

In the report narrative, the BLS noted that the Boeing strike likely subtracted 44,000 jobs in the manufacturing sector, which lost 46,000 positions overall.

​

Along with that, the report noted the impact of hurricanes Helene and Milton but said “it is not possible to quantify the net effect” of the storms on the jobs total.

Elsewhere, the bureau said average hourly earnings increased 0.4% for the month, slightly higher than the estimate, though the 4% 12-month gain was in line. The average work week held steady at 34.3 hours.

Markets, though, largely ignored the bad news, with stock market futures poised for a strong open on Wall Street while Treasury yields plunged. The meager jobs numbers along with wages about in line with expectations help cement another interest rate cut from the Federal Reserve next week.

​

The release comes just days ahead of the presidential election in which Democrat Kamala Harris and Republican Donald Trump are in what most polls show to be a deadlocked race. With the economy at the forefront of the battle, the light jobs number “casts a murky shadow heading into next week,” said Lisa Sturtevant, chief economist at Bright MLS.

The weak October report also included substantial downward revisions from previous months. August was cut to just a gain of 78,000 while September’s initial estimate came down to 223,000. Together, the net revisions lowered previously reported job creation totals by 112,000.

​

Health care and government again led job creation, respectively adding 52,000 and 40,000 positions. Several sectors, though, saw job losses.

In addition to the expected pullback in manufacturing, temporary help services saw a drop of 49,000. The category is sometimes seen as a proxy for underlying job strength and has seen a decline of 577,000 since March 2022, the BLS said.

Another leading sector, leisure and hospitality, saw a drop of 4,000, while retail trade and transportation and warehousing also reported modest declines.

The report covers a month in which hurricanes Helene and Milton slammed the Southeast – Florida and North Carolina in particular – while the Boeing strike also hit what had been a vibrant though slowing labor market. Recent developments indicate that the Boeing impasse, which sidelined some 44,000 workers, could be near an end.

Prior to the release, job creation had averaged close to 200,000 a month during 2024, about 60,000 below the pace for the same period a year ago through still indicative of solid pace of hiring.

Some cracks in recent months have raised concerns at the Federal Reserve that while the year-over-year pace of inflation is slowing, elevated interest rate could impact the labor market and threaten the ongoing economic expansion.

As a result, policymakers in September took a step unprecedented for a growing economy and lowered their benchmark short-term interest rate by half a percentage point, double the customary quarter-point increments in which the Fed usually likes to move.

Financial markets are pricing in a strong likelihood that the central bank cuts by a quarter point at each of its two remaining meetings this year. The rate-setting Federal Open Market Committee will announce its decision next Thursday.

Uk guy here, currently have quite a bit of money invested in the SandP500. Do you think it’s worth removing it for 2 weeks till this election storm blows over?

I personally think it’s 50/50 however if Democrats get in, I can see a Trump stealing the election madness for a few days tanking stocks. What’s everyone’s thoughts?

https://www.reddit.com/r/stocks/s/tlFJFSppw6

^ Here is a comment(not mine) on an old post about Carvana. I found it extremely illuminating at the time and think now is a good time to share it.

Carvana was around $4-$10/share at the time, and the prevailing sentiment on this sub was:

“If the price is above $0, then Carvana is overvalued.”

^ This type of thinking is DEATH to value investing. Also, to be absolutely clear, I do not think, or know, if Carvana was worth investing in at $10, or $4. I didn’t invest in it, and I don’t know what the right price was. If you win the lottery, that doesn’t mean it was a smart investment. If your odds to win were 1 in 100 million, and you spent $5 and won $10 million, it was a bad investment.

If Carvana went to $0, which it was likely to do, the idea that there is no price at which it was worth investing in is ludicrous.

Every single company in the world is worth buying at the right price. Period.

The question is, what’s the right price?

Let this be a reminder that good fundamental analysis and high IQ is meaningless if you dont have the right mindset for value investing.

Edit: If you think that price doesn’t matter for certain companies, which is the opinion that is required to disagree with this post, what is your argument? I think people here just wrongly view this post as “look, this guy said Carvana was worth considering at $4, therefore he is smart.”

If I had removed Carvana from the equation, or Carvana had gone to $0, what would your argument be against the idea that all companies are worth investing in at the right price?

This is the daily discussion, so anything stocks related is fine, but the theme for today is on fundamentals, but if fundamentals aren't your thing then just ignore the theme.

Some helpful day to day links, including news:

• Finviz for charts, fundamentals, and aggregated news on individual stocks
• Bloomberg market news
• StreetInsider news:
  • Market Check - Possibly why the market is doing what it's doing including sudden spikes/dips
  • Reuters aggregated - Global news

Most fundamentals are updated every 3 months due to the fact that corporations release earnings reports every quarter, so traders are always speculating at what those earnings will say, and investors may change the size of their holdings based on those reports.

Expect a lot of volatility around earnings, but it usually doesn't matter if you're holding long term, but keep in mind the importance of earnings reports because a trend of declining earnings or a decline in some other fundamental will drive the stock down over the long term as well.

But growth stocks don't rely so much on EPS or revenue as long as they beat some other metric like subscriber count: Going from 1 million to 10 million subscribers means more revenue in the future.

Value stocks do rely on earnings reports, investors look for wall street expectations to be beaten on both EPS & revenue. You'll also find value stocks pay dividends, but never invest in a company solely for its dividend.

See the following word cloud and click through for the wiki:

Market Cap - Shares Outstanding - Volume - Dividend - EPS - P/E Ratio - EPS Q/Q - PEG - Sales Q/Q - Return on Assets (ROA) - Return on Equity (ROE) - BETA - SMA - quarterly earnings

If you have a basic question, for example "what is EBITDA," then google "investopedia EBITDA" and click the Investopedia article on it; do this for everything until you have a more in depth question or just want to share what you learned.

Useful links:

• Investopedia page on fundamental analysis including Discounted Cash Flow analysis; see definition here and read their PDF on the topic.
• FINVIZ for fundamental data, charts, and aggregated news
• Earnings Whisper for earnings details

See our past daily discussions here. Also links for: Technicals Tuesday, Options Trading Thursday, and Fundamentals Friday.

Hi, I have 3 broker accounts (Schwab, Fidelity, IB) each with a mix of equity (long and short) and options. I can't find a single existing software that can accurately track performance of all 3 accounts. Most of the off the shelf software I've tried has trouble with either shorts, options, or both.

Has anyone found a solution to monitoring multiple accounts with both equity and options? Thank you!

Amazon CEO Andy Jassy is trying to reassure investors who may be worried about the future payoff of the company’s massive investments in generative artificial intelligence.

On a conference call with analysts following the company’s third-quarter earnings report on Thursday, Jassy pointed to the success of Amazon’s cloud computing business, Amazon Web Services, which has become a crucial profit engine despite the extreme costs associated with building data centers.

“I think we’ve proven over time that we can drive enough operating income and free cash flow to make this a very successful return on invested capital business,” Jassy said. “We expect the same thing will happen here with generative AI.”

Amazon spent $22.6 billion on property and equipment during the quarter, up 81% from the year before. Jassy said Amazon plans to spend $75 billion on capex in 2024 and expects an even higher number in 2025.

The jump in spending is primarily being driven by generative AI investments, Jassy said. The company is rushing to invest in data centers, networking gear and hardware to meet vast demand for the technology, which has exploded in popularity since OpenAI released its ChatGPT assistant almost two years ago.

“It is a really unusually large, maybe once-in-a-lifetime type of opportunity,” Jassy said. “And I think our customers, the business and our shareholders will feel good about this long term that we’re aggressively pursuing it.”

AI spending was a big topic on tech earnings calls this week. Meta on Wednesday raised its capital expenditures guidance, and CEO Mark Zuckerberg said he was “quite happy” with the team’s execution. Meanwhile, Microsoft’s investment in OpenAI weighed on its fiscal first-quarter earnings released on Wednesday, and the company said capital spending would continue to rise. A day earlier, Alphabet CFO Anat Ashkenazi warned the company expects capital spending to grow in 2025.

Amazon has said its cloud unit has picked up more business from companies that need infrastructure to deploy generative AI models. It’s also launched several AI products for enterprises, third-party sellers on its marketplace and advertisers in recent months. The company is expected to announce a souped-up version of its Alexa voice assistant that incorporates generative AI, something Jassy said will arrive “in the near future.”

Amazon hasn’t disclosed its revenue from generative AI, but Jassy said Thursday it’s become a “multi-billion-dollar revenue run rate” business within AWS that “continues to grow at a triple-digit year-over-year percentage.”

“It’s growing more than three times faster at this stage of its evolution as AWS itself grew, and we felt like AWS grew pretty quickly,” he added.

Source: https://www.cnbc.com/2024/10/31/amazon-ceo-pledges-ai-investments-will-pay-off-as-capex-surges-81percent.html

Coinbase shares were under pressure Thursday, a day after the company reported weaker-than-expected earnings and gave a tepid revenue outlook for the current quarter.

The stock lost 15.3%, its biggest drop since May 2022, when it fell 19.5%. A broader market decline also pressured Coinbase.

Other crypto-related stocks fell as well. Robinhood, which also reported weak earnings Wednesday, tumbled 16%. Miners Mara Holdings and Riot Platforms slid 8% and 11%, respectively.

Bitcoin, which is often a big influence on the price of Coinbase, slid 2.78% to $69,918.66 after hovering below its all-time high of $73,000 this week.

Devin Ryan, an analyst at JMP Securities, chalked it up to a temporary unwind in crypto-related names and called it an opportunity for longer-term focused investors in Coinbase and Robinhood.

“There is a lot that’s going to happen here over the next couple months – [like] the U.S. election [and] ramifications of that – that will be become the much bigger story for the space, not to mention the recent appreciation in crypto prices and volume could put upward pressure on fourth-quarter revenue if the trend continues over the next two months,” said Ryan, who has an outperform rating on Coinbase.

“Near-term, people will have to recalibrate a bit in their models for the blended take rate assumption,” or the percentage of revenue Coinbase keeps from a transaction, he said. “Nothing structural occurred here, but as stablecoin trading volume has increased, that comes at a lower spread, and the fourth-quarter implied revenue guide was a bit soft.”

Owen Lau, an analyst at Oppenheimer with a buy rating on Coinbase, put Thursday’s drop on the warning that subdued volume could persist going forward and that lower U.S. interest rates could cut into the growth of Coinbase’s stablecoin revenue.

Source: https://www.cnbc.com/2024/10/31/crypto-market-today.html

The S&P 500 and the Nasdaq Composite were in a free fall today losing 1.9% and 2.8% respectively, - a rout as traders and investors turned their noses up at Meta and Microsoft’s earnings. Even Google has given up its 5% gain from yesterday. Matching the drop, the VIX closed at 23.16, and the 10-year Treasury Yield closed about the same at 4.29%.

Should Apple and Amazon disappoint post-market today, I think a correction could be on. The main bullish factor countering a volatile election week, a VIX over 23 and high yields of 4.3% is strong earnings, especially from the M-7. Clearly, that doesn’t seem to be happening.

Meta - Initially, it seemed like a perfunctory one percent drop on a small beat and in-line guidance, but it’s gone a lot further as Meta is down 4% to 570.

Why the rout? Analysts and investors panned high Capex plans of $40Bn and costly high-risk bets such as Meta’s Reality Labs unit, (the developer of augmented and virtual reality technologies), which logged a staggering operating loss of $4.4 billion

Microsoft - (down 6% to $408) is getting clobbered for a different reason. Even as Azure grew 34%, the pace wasn’t enough, and guidance of 31% to 32% in constant currency was lower than expected. However, this is due to supply chain constraints as President Amy Hood noted that the 1 or 2-point deceleration Microsoft has guided is mainly due to some supply pushouts, in terms of AI supply coming online that the company counted on. (Read, not as many Blackwells/Hoppers as they would have liked)

"We expect consumption growth to be stable compared to Q1, and we expect to add more sequential dollars to Azure than any other quarter in history," Hood added.

The indomitable Dan Ives of Wedbush remains as bullish as ever…

"We actually disagree with this initial take as the new Azure reporting standards have moved Street numbers all around and a slight deceleration is totally expected by many investors with some supply constraints and reacceleration in 2H25, and we would be strong buyers of MSFT on any weakness this morning," Wedbush analysts, led by Daniel Ives, said in a note.

Apple Earnings: https://investor.apple.com/investor-relations/default.aspx

CUPERTINO, Calif.--(BUSINESS WIRE)--Apple® today announced financial results for its fiscal 2024 fourth quarter ended September 28, 2024. The Company posted quarterly revenue of $94.9 billion, up 6 percent year over year, and quarterly diluted earnings per share of $0.97. Diluted earnings per share was $1.64,1 up 12 percent year over year when excluding the one-time charge recognized during the fourth quarter of 2024 related to the impact of the reversal of the European General Court’s State Aid decision.

“Today Apple is reporting a new September quarter revenue record of $94.9 billion, up 6 percent from a year ago,” said Tim Cook, Apple’s CEO. “During the quarter, we were excited to announce our best products yet, with the all-new iPhone 16 lineup, Apple Watch Series 10, AirPods 4, and remarkable features for hearing health and sleep apnea detection. And this week, we released our first set of features for Apple Intelligence, which sets a new standard for privacy in AI and supercharges our lineup heading into the holiday season.”

“Our record business performance during the September quarter drove nearly $27 billion in operating cash flow, allowing us to return over $29 billion to our shareholders,” said Luca Maestri, Apple’s CFO. “We are very pleased that our active installed base of devices reached a new all-time high across all products and all geographic segments, thanks to our high levels of customer satisfaction and loyalty.”

Apple’s board of directors has declared a cash dividend of $0.25 per share of the Company’s common stock. The dividend is payable on November 14, 2024 to shareholders of record as of the close of business on November 11, 2024.

Apple will provide live streaming of its Q4 2024 financial results conference call beginning at 2:00 p.m. PT on October 31, 2024 at apple.com/investor/earnings-call. The webcast will be available for replay for approximately two weeks thereafter.

Intel shares jumped 12% in extended trading on Thursday after the chipmaker reported better-than-expected revenue and issued quarterly guidance that topped expectations.

Here’s how the company did in comparison with LSEG consensus:

• Earnings per share: Loss of 46 cents adjusted
• Revenue: $13.28 billion vs. $13.02 billion expected

Intel’s revenue declined 6% year over year in the quarter, which ended on Sept. 28, according to a statement. The company registered a net loss of $16.99 billion, or $3.88 per share, compared with net earnings of $310 million, or 7 cents per share, in the same quarter a year ago.

As part of its cost reduction plan, Intel recognized $2.8 billion in restructuring charges during the quarter. There were also $15.9 billion in impairment charges.

Intel has been mired in an extended slump due to market share losses in its core businesses and an inability to crack artificial intelligence. CEO Pat Gelsinger revealed plans during the quarter to turn the company’s foundry business into an independent subsidiary, a move that would enable outside funding options.

CNBC reported that Intel had engaged advisors to defend itself against activist investors. In late September, news surfaced that Qualcomm reached out to Intel about a possible takeover.

The Client Computing Group that sells PC chips recorded $7.33 billion in revenue, down about 7% from a year earlier and below the $7.39 billion consensus among analysts surveyed by StreetAccount.

Revenue from the Data Center and AI segment came to $3.35 billion, which was up about 9% and more than the $3.17 billion consensus from StreetAccount.

Intel called for fiscal third-quarter adjusted earnings of 12 cents per share and revenue between $13.3 billion and $14.3 billion. Analysts had expected 8 cents in adjusted earnings per share and $13.66 billion in revenue.

During the quarter, Intel announced the launch of Xeon 6 server processors and Gaudi artificial intelligence accelerators.

As of Thursday’s close, Intel shares were down about 57% in 2024, while the S&P 500 index had gained 20%.

Source: https://www.cnbc.com/2024/10/31/intel-intc-q3-earnings-report-2024.html

Amazon Earnings: https://www.businesswire.com/news/home/20241030305950/en/Amazon.com-Announces-Third-Quarter-Results

SEATTLE--(BUSINESS WIRE)--Amazon.com, Inc. (NASDAQ:AMZN) today announced financial results for its third quarter ended September 30, 2024.

Net sales increased 11% to $158.9 billion in the third quarter, compared with $143.1 billion in third quarter 2023.

Excluding the $0.2 billion unfavorable impact from year-over-year changes in foreign exchange rates throughout the quarter, net sales increased 11% compared with third quarter 2023.

North America segment sales increased 9% year-over-year to $95.5 billion.

International segment sales increased 12% year-over-year to $35.9 billion.

AWS segment sales increased 19% year-over-year to $27.5 billion.

Operating income increased to $17.4 billion in the third quarter, compared with $11.2 billion in third quarter 2023.

North America segment operating income was $5.7 billion, compared with operating income of $4.3 billion in third quarter 2023.

International segment operating income was $1.3 billion, compared with an operating loss of $0.1 billion in third quarter 2023.

AWS segment operating income was $10.4 billion, compared with operating income of $7.0 billion in third quarter 2023.

Net income increased to $15.3 billion in the third quarter, or $1.43 per diluted share, compared with $9.9 billion, or $0.94 per diluted share, in third quarter 2023.

Operating cash flow increased 57% to $112.7 billion for the trailing twelve months, compared with $71.7 billion for the trailing twelve months ended September 30, 2023.

Free cash flow increased to $47.7 billion for the trailing twelve months, compared with $21.4 billion for the trailing twelve months ended September 30, 2023.

Free cash flow less principal repayments of finance leases and financing obligations increased to $44.9 billion for the trailing twelve months, compared with $15.9 billion for the trailing twelve months ended September 30, 2023.

Free cash flow less equipment finance leases and principal repayments of all other finance leases and financing obligations increased to $46.1 billion for the trailing twelve months, compared with $20.2 billion for the trailing twelve months ended September 30, 2023.

HIMS is up 94% YTD and largely due to their approval to sell semaglutide, the active ingredient in Ozempic. The company has been compounding this medication themselves, due to the FDA defining the drug as in shortage. This definition allows 3rd party pharmacies to make and sell the drug on their own without waiting for generics to come out (which can be years).

Now that the shortage is over HIMS greatest growth driver is no longer a viable long term strategy.

https://www.fiercepharma.com/pharma/fda-clears-novos-wegovy-shortage-list-marking-end-semaglutide-supply-rout-us

ENVX and why it will moon

ENVX (Enovix) is an advanced lithium-ion silicon battery manufacturer, and is a first mover with it's battery. They already have 2 smartphone OEMs lined up for 2025, and they just finished their fab2 in Malaysia. They have a patent to protect their proprietary process behind their silicon batteries. They are the first to use 100% active silicon batteries in the consumer market. Competitors cannot just spin up a fab easily.

They are positioned to ramp up production in 2025 with profits coming in early 2026.

They recently raised $100m via stockholder dilution, out of their 168m total outstanding shares. This is roughly only 6% dilution. As of today, their share price has dropped 19%. The $100m dilution along with $200m cash on hand, allows them to survive for 6 more quarters at a minimum, assuming they still continue to burn $50m in cash per quarter, without any efficiency gains. That positions that well for the beginning of 2026 play. More partnerships, more customers, lower CAPEX, different segments of customers, will all drive the price up.

Next-gen batteries and EVs and component manufacturers are a long-term play

I believe ENVX is currently underpriced. As of current price $8.45, my EOY price target is $12, and by end of next year, I see $18 at a minimum.

I had recommended Alphabet (GOOG) as a great long-term buy at $150, several months ago.

Last evening, Google knocked it out of the park with really stellar results. I bought more shares this morning, and am reiterating a Buy.

I believe analysts’ consensus earnings could be a little conservative and Google should continue to beat estimates with better growth and operating margins.

Google's earnings quality is better than several tech giants for the following reasons.

• It has a near monopoly in Search
• Market leadership in media with YouTube.
• A strong first-mover advantage with Waymo.
• A fast-growing Google Cloud business, third only to and catching up with Azure and AWS.

Its earnings and growth are sustainable, thus it deserves a better valuation and multiple.

Let's take a closer look at Q3 earnings.

Q3 GAAP EPS came in at $2.12 per share, beating expectations of $1.85 per share $0.27, or 14% - This was a substantial beat.

Revenue of $88.3Bn (+14.9% Y/Y) beat by $2.05B or 3%.

Consolidated Alphabet revenues in Q3 2024 increased 15%, or 16% in constant currency, YoY to $88.3Bn reflecting strong momentum across the business.

Google Services revenues increased 13% to $76.5 billion, led by strength across Google Search & other, Google subscriptions, platforms, and YouTube ads.

Total operating income increased 34% and operating margin percent jumped a huge 4.5% to 32%.

Google Cloud revenues grew a whopping 35% to $11.4Bn led by accelerated growth in Google Cloud Platform (GCP) across AI Infrastructure, Generative AI Solutions, and core GCP products, with record operating margins of 17% as the cost per AI query decreased by 90% over the past 18 months.

Cloud titans Amazon (AWS) and Microsoft (Azure) have commanded huge valuations for their cloud computing businesses; with Google Cloud growing at 35%, it should continue to narrow the gap over the next 5 years. Also importantly, AWS and Azure have operating margins over 30%, and should Google continue to scale and leverage their existing fixed costs, they can reach the same margins. I also believe as they get better at AI, they should be able to charge more.

Based on consensus analysts’ estimates Alphabet’s EPS should grow to $11.60 in 2027 from $5.80 in 2023 - that’s an annual growth rate of 18%. Comparatively, Apple‘s estimated EPS growth through FY2027 is slower at 14%, and it sports a P/E of 33 compared to Google’s 22. Alphabet’s P/E is closer to the S&P 500’s P/E of 21!

I believe this is too low, and there is a lot of potential for its stock to appreciate on the lower valuation.

Besides the strong EPS, a lot of Google’s expenses are noncash depreciation and amortization and their cash flow margins are strong. They generated operating cash of $31Bn on $88Bn last quarter, or a 35% cash flow margin.

The antitrust regulation will remain a possible negative on Alphabet, but the final decision is still years away as Alphabet vigorously appeals the decision.

I recommend Alphabet as a buy at $176

I am not trying to understand if Carvana's price is unfair or fair.

I am trying to understand if Carvana is possibly a fraud and a great put opportunity or not.

The gross profit they are claiming to make is over $7,000 a car.

Is this because they get part of the financing/rebate/etc?

I know several car dealers and the #s don't make sense to them.

The flip side is that this is the equivalent of In and Out. In and Out prints money and operates at a different level than any other fast food restaurant.

Charles Schwab, a leader in investing and trading with $9.92 trillion in total client assets that facilitates approximately six million daily average trades, today announced it will begin piloting additional access to the overnight trading session by expanding to include stocks in the S&P 500, Nasdaq-100 and hundreds of additional exchange-traded funds (ETFs) available for trading 24 hours a day, five days a week (24/5).

https://www.businesswire.com/news/home/20241030440846/en/Schwab-to-Significantly-Expand-Its-24-Hour-Trading-Capabilities-to-Include-the-Stocks-in-the-SP-500%C2%AE-Nasdaq-100%C2%AE-and-Hundreds-of-Additional-Exchange-Traded-Funds

Is Warren Buffet shopping today? What's on your to buy or DCA list when the market turns red?

Advice and recommendations are welcome.

I'm actually looking possibly at PLTR or NVDA but ideas are all welcome for the next red day.

I posted about reddit stock a few weeks ago with a general mindset while it was in the 70s its potentially undervalued, but since their earnings report 2 days ago this went from 84 to current 120s and rising.

While I believe longer term it's possible for them to grow more into the valuation wallstreet is pumping on the ticker, it's up 45% in a day and a half.

Its the nature of the beast sometimes for a stock to uncontrollably run up. It's rare a stock stays up that high. Only exception to the rule is something like tsla stock.

Is anyone buying post earnings in the triple digits? If so, what's your target or are you just chasing/fomoing into this ticker?

Estée Lauder Companies, Inc. (NYSE:EL) shares are trading lower on Thursday.

The company reported first-quarter adjusted earnings per share of 14 cents, beating the street view of 9 cents. Quarterly sales of $3.36 billion (down 4%), missed the analyst consensus estimate of $3.371 billion.

Segmentally, the Skin Care unit sales slumped by 7%, Makeup fell by 2%, Fragrance decreased by 1%, and Hair Care dropped by 6%.

Organic net sales dropped 5% mainly due to declining consumer sentiment in China, leading to weaker prestige beauty sales and low conversion rates in Asia travel retail and Hong Kong SAR. Additionally, lower replenishment orders and inventory pressures from a slowing retail market further affected sales.

In the quarter under review, Estée Lauder reported a net loss of $156 million, compared with net earnings of $31 million in the prior year, primarily due to charges associated with talcum litigation settlement agreements of $159 million in the aggregate.

“With this complex industry landscape, including the particular difficulty in forecasting the timing of market stabilization and recovery in China and Asia travel retail, and in the context of leadership changes, we are solely issuing an outlook for the second quarter and withdrawing our fiscal 2025 outlook,” Fabrizio Freda, President and Chief Executive Officer said.

Yesterday, Estée Lauder announced the appointment of Stéphane de La Faverie as its new President and Chief Executive Officer, effective January 1, 2025. He will also join the Board of Directors, succeeding Fabrizio Freda, who has decided to retire after more than sixteen years with the company.

Estée Lauder exited the quarter with cash and equivalents worth $2.350 billion and inventory and promotional merchandise worth $2.255 billion. Long-term debt as of quarter end totaled $7.31 billion.

Dividend: The company is reducing its dividend which affords more financial flexibility for the incoming leadership team to reaccelerate the profitable growth trajectory.

Estée Lauder declared a quarterly dividend of 35 cents per share payable in cash on December 16.

Outlook: Estée Lauder expects adjusted net earnings per common share to decrease between 77% and 60% and range between 20 cents and 35 cents, significantly below the $1.06 consensus estimate.

For the second quarter, the company’s reported and organic net sales are forecasted to decrease between 8% and 6% versus the prior-year period.

Price Action: EL shares are trading lower by 22.9% to $67.24 premarket at last check Thursday.

Source

Comcast is exploring a separation of its cable networks business, President Mike Cavanagh said Thursday.

During the company’s third-quarter earnings call with investors, Cavanagh said the company is exploring creating “a new, well-capitalized company owned by our shareholders and comprised of our strong portfolio of cable networks.”

The possible separation would not include broadcast network NBC nor streaming service Peacock, he added. NBCUniversal’s cable networks portfolio includes Bravo, E!, Syfy, Oxygen True Crime, USA Network, as well as news networks MSNBC and CNBC.

The company lost 365,000 cable TV customers during the third quarter.

“Like many of our peers in media, we are experiencing the effects of the transition in our video businesses and have been studying the best path forward for these assets,” Cavanagh said.

“We are not ready to talk about any specifics yet, but we’ll be back to you as and when we reach firm conclusions,” he said.

Shares of Comcast were up more than 6% in premarket trading.

The comments come as millions of customers continue to flee the traditional pay TV bundle in favor of streaming. Comcast has been beefing up Peacock, which got a boost during the third quarter when it exclusively aired the Summer Olympics in Paris.

Source: https://www.cnbc.com/2024/10/31/comcast-is-exploring-separation-of-cable-business.html

At the time of writing this post, UBER is down 7% in premarket, which is a big overreaction, after their earnings report. I suspect the cause of the drop is the miss on Bookings, which is not significant in my opinion.

Key factors:

• EPS of $1.20, beating expectations of $0.41

• Revenue of $11.2B, beating expectations of $11B

• Total Gross Bookings of $41B, missing expectations of $43B

UBER had a record quarter, for the first time it generated an all time high GAAP operating profits of more than $1B.

In the conference call the CEO and CFO reiterated that they have a very high standard for doing M&A, so the Expedia deal is not set in stone, rather just a rumor.

They've also stated they are looking to reduce share count in 2025, meaning doing share buybacks, which will in turn drive higher share price.

But what I want to talk mostly about is the AV section.

AV

The AV (Autonomous vehicle or self driving cars) is a hot topic right now, especially after Teslas event. Despite Tesla being clearly very far behind actual FSD, Waymo is doing AV, and doing it good. They are partenered with UBER and the AV fleet actually had the highest rated score on the platform (as mentioned by their CEO in the earnings call). Beside Waymo, they are partenered with 14 AV companies, including Aurora which they also have a big stake in. AV is coming, maybe not now, maybe not next year, but it is inevitably coming. And all these AV, especially the smaller ones, need a platform to operate their fleet. Do you build it from the ground up or join UBER who has 25 million rides a day already?

They are also partnered with BYD for the electrification of their fleet. Guess what is BYD also working on? Yeah, thats right, AVs. And judging BYD/China success on doing EVs, I think thats a pretty good chance they will also succeed on the AV side. And since they are already partenered, where do you think BYDs AV fleet will be used? In UBER.

I think the company is positioned greatly for the future, its profitable after multiple years of negative EPS, it has a clear plan moving forward about their free cash flow, including reducing $2B out of their debt by the end of the year.

Disclaimer, I do have a position in UBER.

$VKTX Full summary for oral regimens and my expectations when $VKTX presents data this weekend (Nov 3, 2024)

Price Target $122 after oral wight loss data by Raymond James, speculation buyout target $150/share ($20 Billion Valuation)

TL;DR = Right now the market leaders in weight loss are $LLY and $NVO with injectable needles. $VKTX is also in this delivery mechanism, but showing better safety in their phase 2a data and got FDA approval to go straight to Phase 3 trails and skipping Phase 2b which is huge news.

Oral Data Catalyst - Nobody likes taking weekly injectables, so an "oral pill" is seen as a gamechanger. Weight loss over 5% is a very competitive number and over 6% will be home run. This is a 28 day trial and not 13 weeks. Pay attention to efficacy and safety of VK2735.

M&A Buyout - There are big pharma companies out there who are not in the weight loss space yet such as Merck $MRK and their $25 billion drug Keytruda going off patent in 2028. $MRK needs to shore up a big revenue source soon and the wight loss drug category is poised to reach $471 Billion by 2032.

Keep in mind $VKTX 2735 showed 3.3% weight loss at 40mg and safety profile similar to Placebo. However, Nov 3rd will show results from high dose cohorts 60mg, 80mg and 100mg.

$LLY Orforglipron showed 3% weight loss, ~ 28% vomiting. 39% Nausea

$NVO two oral drugs

1. Monlunabant- I personally don't see a path for this drug. 3.3% weight loss in 28 days but here comes the safety hammer with drug showing psychiatric issues like anxiety, irritability, and sleep disturbances won't go well with FDA. $SNY drug rimonabant (never got approved) because drug was plagued with CNS issues
2. Amycretin- Weight loss around 4% (don't have the exact number) but safety profile is as worse as CT-996. Nause 75%, Vomiting 56%, diarrhea 18.8%.

Conclusion: For $VKTX the bar is to show weight loss 5-6% or higher to beat competitors and stay competitive with tolerability profile. In my opinion, higher doses will show weight loss > 6% with competitive edge on safety.